Analysts expect that Cerecor Inc (NASDAQ:CERC) will post earnings per share of ($0.17) for the current quarter, Zacks reports. Two analysts have provided estimates for Cerecor’s earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.15). Cerecor posted earnings of ($0.26) per share during the same quarter last year, which would suggest a positive year over year growth rate of 34.6%. The firm is expected to issue its next earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Cerecor will report full-year earnings of ($0.56) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.46). For the next financial year, analysts forecast that the firm will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.64) to ($0.40). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Cerecor.
Cerecor (NASDAQ:CERC) last released its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. Cerecor had a negative return on equity of 143.30% and a negative net margin of 231.68%. The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $5.28 million.
Shares of Cerecor stock traded down $0.20 on Monday, reaching $3.19. 47,716 shares of the stock were exchanged, compared to its average volume of 49,085. The company has a current ratio of 0.74, a quick ratio of 0.71 and a debt-to-equity ratio of 0.81. Cerecor has a twelve month low of $2.71 and a twelve month high of $7.65. The business has a 50 day moving average price of $3.28 and a two-hundred day moving average price of $4.40.
In related news, Director Armistice Capital, Llc purchased 1,000,000 shares of Cerecor stock in a transaction that occurred on Friday, September 6th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $2,950,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Armistice Capital Master Fund purchased 2,200,000 shares of Cerecor stock in a transaction that occurred on Friday, September 6th. The shares were bought at an average price of $3.05 per share, with a total value of $6,710,000.00. The disclosure for this purchase can be found here. Insiders have purchased 4,643,678 shares of company stock valued at $14,224,147 in the last ninety days. Corporate insiders own 64.30% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Cerecor by 56.5% during the second quarter. Vanguard Group Inc. now owns 678,000 shares of the company’s stock valued at $3,689,000 after acquiring an additional 244,657 shares in the last quarter. BlackRock Inc. raised its position in Cerecor by 4,046.6% during the second quarter. BlackRock Inc. now owns 1,205,533 shares of the company’s stock valued at $6,559,000 after acquiring an additional 1,176,460 shares in the last quarter. Northern Trust Corp raised its position in Cerecor by 47.4% during the second quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock valued at $304,000 after acquiring an additional 17,999 shares in the last quarter. Bank of New York Mellon Corp raised its position in Cerecor by 294.9% during the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after acquiring an additional 42,885 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in Cerecor during the second quarter valued at approximately $288,000. Institutional investors own 55.75% of the company’s stock.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Recommended Story: Net Margin
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.